The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...

You could be forgiven if you believed that the FDA granted full approval to Moderna's COVID-19 vaccines for children yesterday. Indeed, that's how many major media outlets portrayed things. After all, ...

Shares of GSK rose on Thursday after the company announced it had begun shipping its seasonal flu vaccines, Fluarix and ...

A CDC advisory panel vote to recommend against use of seasonal influenza vaccines containing small amounts of thimerosal ...

Advisers to the Centers for Disease Control and Prevention recommended against flu shots containing the ingredient thimerosal ...

You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate medical and public health challenges. Click here to ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The trial enrolled more than 40,800 adults 50 and older from 11 countries. “The severity of this past flu season underscores the need for more effective vaccines,” said Stéphane Bancel, chief ...